<DOC>
	<DOCNO>NCT00023881</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness bortezomib treat patient chronic myelogenous leukemia chronic accelerate phase .</brief_summary>
	<brief_title>Bortezomib Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy bortezomib , term response rate , duration response , survival patient Philadelphia chromosome-positive chronic myelogenous leukemia chronic accelerate phase . - Assess toxicity drug patient . OUTLINE : Patients receive bortezomib intravenous ( IV ) 3-5 second twice weekly week 1-2 . Treatment repeat every 3 week 12 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 5-30 patient accrue study within 15-30 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Philadelphia ( Ph ) chromosomepositive chronic myelogenous leukemia ( CML ) chronic accelerate phase , define follow : Peripheral blood ( PB ) bone marrow ( BM ) blast least 10 % le 30 % PB BM blast promyelocytes least 20 % PB BM basophils least 20 % Progressive splenomegaly ( least 10 cm confirm twice least 4 week apart 50 % increase splenomegaly 4 week ) Clonal evolution define presence additional cytogenetic abnormality Ph chromosome Thrombocytopenia ( platelet count le 100,000/mm^3 ) unrelated therapy Hemoglobin le 7 g/dL unrelated therapy bleeding Failed prior treatment imatinib mesylate intolerant , unable , unwilling receive Ineligible higherpriority higherefficacy regimens protocols No blastic phase CML PATIENT CHARACTERISTICS : Age : 18 Performance status : Eastern Cooperative Oncology Group ( ECOG ) 02 Life expectancy : At least 18 week Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Other : No concurrent illness would preclude study entry Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 2 prior cytotoxic regimen addition imatinib mesylate and/or hydroxyurea At least 4 week since prior chemotherapy recover Concurrent hydroxyurea and/or anagrelide allow first 2 course Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : Not specify Other : See Disease Characteristics See Chemotherapy At least 24 hour since prior imatinib mesylate No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
</DOC>